Form 8-K

8-K — Jasper Therapeutics, Inc.

Accession: 0001213900-26-063157

Filed: 2026-06-01

Period: 2026-06-01

CIK: 0001788028

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0292909-8k_jasper.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED JUNE 1, 2026 (ea029290901ex99-1.htm)

GRAPHIC (ea029290901_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0292909-8k_jasper.htm · Sequence: 1

false

0001788028

2026-06-01

0001788028

JSPR:VotingCommonStockParValue0.0001PerShareMember

2026-06-01

0001788028

JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member

2026-06-01

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.

20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

June 1, 2026

JASPER THERAPEUTICS,

INC.

(Exact Name of

Registrant as Specified in its Charter)

Delaware

001-39138

84-2984849

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2200 Bridge Pkwy Suite #102

Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 549-1400

Registrant’s telephone number, including area

code

N/A

(Former Name,

or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading

Symbol)

(Name

of exchange on which registered)

Voting Common Stock, par value $0.0001 per share

JSPR

The Nasdaq Stock Market LLC

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

JSPRW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company

as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act

of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On June 1, 2026, Jasper Therapeutics, Inc. issued a press release announcing

that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic

alternatives aimed at maximizing shareholder value. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on

Form 8-K.

In accordance with General Instructions B.2 of Form 8-K, the information

in this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 7.01 and Item 9.01 of Current

Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference

in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference

in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated June 1, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JASPER THERAPEUTICS, INC.

Date: June 1, 2026

By:

/s/ Herb Cross

Name:

Herb Cross

Title:

Chief Financial Officer

EX-99.1 — PRESS RELEASE, DATED JUNE 1, 2026

EX-99.1

Filename: ea029290901ex99-1.htm · Sequence: 2

Exhibit 99.1

Jasper Therapeutics Announces Exploration of

Strategic Alternatives to Maximize Shareholder Value

REDWOOD CITY, Calif., June 1, 2026 (GLOBE NEWSWIRE)

– Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab,

a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic

inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors

has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives

being evaluated include, among other options, a sale of assets, licensing of assets, collaborations, a sale of the Company, a business

combination, merger or other strategic transaction, or an orderly wind-down of operations.

In connection with this strategic review, Jasper

will continue to evaluate cost-saving measures to preserve cash, and plans to continue to maintain compliance with regulatory and financial

reporting requirements.

Jasper does not have a defined timeline for the

exploration of strategic alternatives and there can be no assurance that the process will result in any strategic alternative being announced

or consummated or that any such strategic alternative will maximize stockholder value. Jasper does not intend to discuss or disclose further

developments during this process unless and until its Board of Directors has approved a specific action or otherwise determined that further

disclosure is appropriate or required by law.

About Jasper

Jasper is a clinical-stage biotechnology company

focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal

antibody that blocks stem cell factor from binding to the KIT receptor, thereby inhibiting signaling through the receptor. This inhibition

disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of

the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently evaluating briquilimab

as a treatment in patients with CSU, CIndU and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy

volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical

facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation

Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,”

“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”

“would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,”

“outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical

matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including

with respect to its potential in mast cell driven diseases such as CSU, CIndU and asthma; Jasper’s exploration of strategic alternatives,

including the intent to maximize shareholder value; the announcement of or consummation of any strategic alternative; Jasper’s intent

to continue to evaluate cost-saving measures to preserve cash and Jasper’s plan to continue to maintain compliance with regulatory

and financial reporting requirements . These statements are based on various assumptions, whether or not identified in this press release,

and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided

for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance,

a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper.

These forward-looking statements are subject to a number of risks and uncertainties, including the risk that the strategic review process

will not result in the identification or consummation of a transaction on terms the Company or its shareholders find attractive or otherwise

increase shareholder value; general economic, political and business conditions; the risk that the potential product candidates that Jasper

develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the

risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release;

the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; Jasper’s ability

to continue as a going concern and its imminent need to raise additional funding to continue its operations; risks related to Jasper’s

ability to manage cash resources and obtain additional cash resources to fund its foreseeable and unforeseeable operating expenses and

capital expenditure requirements; the risk that Jasper may be unable to raise capital to continue its operations and its Phase 2b/3 study

in CSU; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that

Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try

new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the

risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail

to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain

could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient

intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and

other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form

10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s

assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While

Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation

to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments as of any date subsequent

to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

Alex Gray (investors)

Jasper Therapeutics

650-549-1454

agray@jaspertx.com

Media:

media@jaspertx.com

GRAPHIC

Filename: ea029290901_ex99-1img1.jpg · Sequence: 3

Binary file (22890 bytes)

Download ea029290901_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jun. 01, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 01, 2026

Entity File Number

001-39138

Entity Registrant Name

JASPER THERAPEUTICS,

INC.

Entity Central Index Key

0001788028

Entity Tax Identification Number

84-2984849

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2200 Bridge Pkwy Suite #102

Entity Address, City or Town

Redwood City

Entity Address, State or Province

Entity Address, Postal Zip Code

94065

City Area Code

650

Local Phone Number

549-1400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Voting Common Stock, par value $0.0001 per share

Title of 12(b) Security

Voting Common Stock, par value $0.0001 per share

Trading Symbol

JSPR

Security Exchange Name

NASDAQ

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

Title of 12(b) Security

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

Trading Symbol

JSPRW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=JSPR_VotingCommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=JSPR_RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: